Arexera Therapeutics

Arexera Therapeutics, formerly Atalanta Therapeutics, is a clinical-stage biotechnology company developing siRNA medicines for severe neurological diseases. The Company’s proprietary divalent siRNA (di-siRNA) and bispecific siRNA (bi-siRNA) platforms are designed to enable robust and durable gene silencing throughout the brain, including deep brain regions that have historically been difficult to reach. Arexera is advancing a pipeline of therapies directed against genetically validated drivers of disease, with an initial focus on Huntington’s disease, pursuing complementary approaches with ATL-101, targeting HTT, and MSH3-directed strategies, as well as future opportunities across other severe neurological diseases. The Company is also advancing partnered programs as part of a strategic collaboration with Genentech. Arexera is headquartered in Boston, Mass.